Stifel downgraded Clearside Biomedical (CLSD) to Hold from Buy with a price target of $2, down from $8. In a challenging financing environment, Clearside has arrived at the end of its cash runway with no new injection of capital and is now considering strategic alternatives, the analyst tells investors in a research note. The firm added that, given the company has been seeking capital influx for some time for further development of CLS-AX, the outcome of its new efforts to preserve cash and maximize the remaining value in its platform is uncertain.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Needham downgrades Clearside on ‘disappointing’ decision to explore options
- Clearside Biomedical downgraded to Hold from Buy at Needham
- Clearside Biomedical downgraded to Hold from Buy at JonesResearch
- Hold Rating for Clearside Biomedical Amid Strategic Uncertainty and Financial Constraints
- Clearside Biomedical Explores Strategic Alternatives Amid Economic Challenges